EU H2020 Project "EPITARGET (Epigenome-targeted therapy for cholangiocarcinoma.)": description, partecipants, costs and EC-fundings

#	Pagina
attuale pagina	/open-h2020/projects/203987/index.html

EpiTarget project word cloud

Explore the words cloud of the EpiTarget project. It provides you a very rough idea of what is the project "EpiTarget" about.

epigenomic time expertise surviving expert achilles epimutation vitro view andersen epi jesper deluge anti dr chemotherapy therapy editing intrinsically greatest hepatobiliary genomics comprise enzymatic prompting turning data for treatment sexes supervised mortality researcher reversible neoplastic patients unmet malignancy broaden cca phenotypic extensively sequencing drug bank translational accordingly optimal escalating mutations cholangiocarcinogenesis expansive screen clinic palliative compare devastating rescue point exacerbating accomplishment myself bio vivo cellular versus prognosis intractable epigenetic transferable rates underpin acting curative deep benefit gt manipulation carry 70 patient virtually world therapeutic global lesions clarify epigenome demographic heel plan draw breaking epimutations first diagnosis models independent abysmal epigenomics streamline enzymes molecular cancer scientific architecture clinical skills cholangiocarcinoma crispr unlike 0 recurrent

Project "EpiTarget" data sheet

The following table provides information about the project.

Coordinator	KOBENHAVNS UNIVERSITET Organization address address: NORREGADE 10 city: KOBENHAVN postcode: 1165 website: www.ku.dk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Denmark [DK]
Project website	https://www.bric.ku.dk/Research/andersen-group/
Total cost	200˙194 €
EC max contribution	200˙194 € (100%)
Programme	1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
Code Call	H2020-MSCA-IF-2015
Funding Scheme	MSCA-IF-EF-ST
Starting year	2017
Duration (year-month-day)	from 2017-02-01 to 2019-01-31

#	participants	country	role	EC contrib. [€]
1	KOBENHAVNS UNIVERSITET	DK (KOBENHAVN)	coordinator	200˙194.00

KOBENHAVNS UNIVERSITET

DK (KOBENHAVN)

coordinator

200˙194.00

Project objective

For > 70% of cholangiocarcinoma (CCA) patients, no curative treatment is available at time of diagnosis and they proceed directly to palliative chemotherapy with virtually 0% surviving at 5 years. Breaking overall cancer trends, CCA mortality rates are escalating among both sexes in the EU, exacerbating this clinical demographic of intractable patients. Recently, a deluge of deep sequencing studies have identified recurrent mutations in epigenetic enzymes in CCA, prompting a turning point in our view of the molecular architecture of this devastating malignancy. Unlike traditional mutations, epigenetic lesions or ‘epimutations’ are intrinsically reversible and, therefore, may comprise an optimal Achilles heel to target for therapeutic benefit. However, to streamline epigenome-driven therapy to the clinic, we first need to clarify molecular and cellular responses to epigenetic manipulation in different CCA models. Accordingly, I have 3 specific objectives of this proposal: i) I plan to carry out a comprehensive in vitro epi-drug screen to determine which enzymatic targets have the greatest anti-neoplastic activity; from this, ii) I will characterize the epigenomic changes that underpin such phenotypic rescue; finally, iii) I will compare the therapeutic effects of the top global-acting epi-drug versus target-specific epigenetic editing (Epi-CRISPR) of the most recurrent epimutation in vivo. Accomplishment of these objectives will improve our understanding of cholangiocarcinogenesis and also address the unmet clinical need for novel therapeutic targets in this cancer demographic with abysmal prognosis. The project will be supervised by Dr. Jesper Andersen, a world-leading expert in hepatobiliary cancer genomics, and will draw extensively on his expansive patient bio- and data-bank. Through this work, I aim to broaden my scientific expertise (including technical and transferable skills) and to establish myself as an independent researcher in translational epigenomics.

Publications

List of publications.
year	authors and title	journal	last update
2018	Chirag Nepal Colm J. O\'Rourke Douglas V.N.P. Oliveira Andrzej Taranta Steven Shema Prson Gautam Julien Calderaro Andrew Barbour Chiara Raggi Krister Wennerberg Xin W. Wang Anja Lautem Lewis R. Roberts Jesper B. Andersen Genomic perturbations reveal distinct regulatory networks in intrahepatic cholangiocarcinoma published pages: 949-963, ISSN: 1527-3350, DOI:	Hepatology 68(3)	2019-09-02
2018	Colm J.O\'Rourke, Patricia Munoz-Garrido, Esmeralda L.Aguayo, Jesper B.Andersen Epigenome dysregulation in cholangiocarcinoma published pages: 1423-1434, ISSN: 0925-4439, DOI:	Biochimica et biophysica acta - Molecular basis of disease Volume 1864, Issue 4, Part B	2019-09-02

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EPITARGET" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EPITARGET" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)